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tBHQ3 genes (SERCA1–3), each of which giving rise to various isoforms. To date,
detailed structural data is only available for the SERCA1a isoform. Here, limited trypsinolysis of either human
platelet membranes or recombinant SERCA3a in HEK-293 cells followed byWestern blotting using antibodies
covering different regions of the SERCA3(a) protein revealed two, kinetically distinct, Early (ETF) and Late
(LTF) Tryptic Fragmentations. The ETF uses many tryptic sites while the LTF uses a unique tryptic site. Using
site-directed mutagenesis: i) Arg334, Arg396 and Arg638 were directly assigned to the ETF and ii) Arg198 was
assigned as the only tryptic site to the LTF. Arg671, Lys712/Lys713 and Lys728 were also found to modulate the
ETF. SERCA inhibitors Tg and tBHQ induced modest inhibition of the ETF. In contrast, the addition of CaCl2,
EGTA or AlF4− strikingly modiﬁed the ETF without any effect on the LTF. Trypsinolysis of the other recombinant
SERCA3b–3f isoforms revealed: i) same ETF and LTF as SERCA3a, with variations of the length of the C-
terminal fragments; ii) Arg1002 as an additional tryptic site in SERCA3b–3e isoforms. Taken together, the two
distinct SERCA3 fragmentation proﬁles sign the co-expression of SERCA3 proteins in two conformational
states in cell membranes.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe sarco(endo)plasmic reticulum Ca2+ ATPases (SERCAs) trans-
port Ca2+ against an electrochemical gradient from the cytoplasm into
the intracellular membranous compartment of the sarcoplasmic or
endoplasmic reticulum and play a major role in Ca2+ homeostasis in
both muscle and non-muscle cells. SERCA proteins are encoded by a
multigenic family that includes 3 (ATP2A1–3) genes. Each gene gives
rise to alternatively spliced isoforms. Until recently, SERCA1 and
SERCA2 genes were known to generate two isoforms, which differ in
their C-termini. They are mainly expressed in adult (SERCA1a) and
neonatal (SERCA1b) skeletal muscles, in cardiacmuscle (SERCA2a) and
in all cell types (SERCA2b). Very recently, we described a new human
SERCA2c isoform [1]. The third gene, SERCA3, was also recently shown
to have various 3′-end splice variants encoding species-speciﬁcm Ca2+ ATPase; E2 and E1,
argin; tBHQ, 2,5-di-tert-butyl-
; ETF, Early Tryptic fragmenta-
+33 01 53 21 67 39.
l rights reserved.isoforms with different C-termini, including 5 SERCA3b–3f variants
in humans, 2 SERCA3b–3c in mice and 1 SERCA3b/c in rats, in addition
to the species-unspeciﬁc SERCA3a isoform [2].
The ion-translocation cycle of SERCAs is conventionally explained
by the E1/E2 theory, where E1 and E2 refer to the high and low Ca2+-
afﬁnity states, respectively. Gating of the ion pathway is coupled to
autophosphorylation and dephosphorylation of the Ca2+ pump.
Phosphoryl transfer from ATP to an Asp in the cytoplasmic domain
(i.e., E1.2Ca2+→E1P) closes the cytoplasmic gate, and the release of
ADP triggers a change in the afﬁnity of the Ca2+ binding sites
(E1P→E2P) and the opening of the luminal gate. Hydrolysis of the
aspartylphosphate (E2P→E2) closes the gate. X-ray crystallography of
SERCA1a has established that along with a transmembrane domain,
this pump consists of three cytoplasmic domains (A, actuator, P,
phosphorylation and N, nucleotide binding) that undergo very large
domain movements during the reaction cycle. Recent progress in
crystallography has yielded high-resolution structures from SERCA1a
in various conformations [3–6]. However, crystals of proteins are
usually obtained under conditions that may differ from physiological
conditions. In addition, these ﬁndings concern the SERCA1a isoform,
exclusively. Consequently, no structural data is available on SERCA3. A
study of SERCA3 gene products is of interest for a number of reasons
(see Discussion). Of note, early studies revealed a number of functional
particularities of SERCA3a in the SERCA family including its lower
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proteins [7]. This lower Ca2+ afﬁnity of SERCA3a was somewhat
unexpected. Among the explanations, it was proposed that the
reduced Ca2+ afﬁnity of SERCA3a might reﬂect an alteration in the
E1 to E2 equilibrium during the ion translocation by this enzyme.
Of a potential interest, in an earlier study, analysis of acylpho-
sphate intermediate (E∼P) formation and the PL/IM430 antibody
(raised against PLatelet Intracellular Membranes) recognition of
platelet Ca2+ ATPases and their proteolytic fragments upon trypsi-
nolysis, revealed two tryptic fragmentation patterns of the so-called
97-kDa SERCA, identiﬁed later as SERCA3a [8]. The ﬁrst pattern
resulted in the formation of a 73/68-kDa intermediary doublet
fragment and, on a second tryptic cleavage, the production of a 40-
kDa fragment previously unknown in the SERCA family. All of these
were immunostained by the PL/IM430 antibody. In a later work, by
performing an immunoprecipitation using a PL/IM430-afﬁnity matrix
in combination with the N89 anti-SERCA3 antibody [9], we
documented that the epitope for the PL/IM430 antibody could be
localized in the SERCA3-related N-terminal 40-kDa tryptic fragment
[10]. However, the relevance to SERCA3 of the PL/IM430-recognizable
fragments could only be deﬁnitely established when the epitope of
the antibody was determined. Chandrasekera et al. demonstrated
that PL/IM430 antibody is a pan-SERCA3 antibody that binds to the
so-called actuator (A) domain, which comprises a tightly folded
independent structure containing aa 1–40 and 126–230 of SERCA3
[11]. The second tryptic fragmentation pattern of the 97-kDa SERCA
resulted in the late production of an E∼P-forming 80-kDa fragment
not recognized by PL/IM430. Initially detected by different groups
using trypsinolysis of native platelet membranes [8,12–15], this 80-
kDa fragment was recovered later on through trypsinolysis of
recombinant human SERCA3a protein [9]. Subsequently, progress in
the structure of SERCA1a [3–6] showed that the accessibility of the
T2 tryptic site (Arg198) that gives rise to a fragment of similar MW
depended on the SERCA1a conformational state.
In the present work, we aim to identify these two tryptic
fragmentation proﬁles as the ones coming from two conformational
states of SERCA3. We approached this issue primarily by performing
trypsin-induced proteolysis coupled with site-directed mutagenesis
experiments that appeared to be a successful approach during
structural/functional studies of the SERCA1a isoform [16–18].
2. Materials and methods
2.1. Platelets
Human blood was obtained from healthy volunteers and the
investigation was performed according to the requirements of the
Helsinki Declaration. The platelets were isolated as described
previously [19].
2.2. Cell culture
A human embryonic kidney (HEK-293) cell line was obtained from
the American Type Culture Collection (Manassas, VA). Cells were grown
in RPMI 1640 mediumwith Glutamax-I, supplemented with 10% heat-
inactivated fetal calf serum, 100 U/ml penicillin and 100 μg/ml
streptomycin.
2.3. Stable and transient transfection in HEK-293 cells
cDNAs for transfection were puriﬁed using a plasmid puriﬁcation
kit (Macherey-Nagel, Düren, Germany). Cells were transfected with
10 μg of the cDNAs using the transfection agent ExGen 500
(Euromedex, Souffelweyersheim, France). Stable transfections have
been described previously [20,21]. For transient transfections, cells
were cultured for 48 h.2.4. Construction of SERCA3 mutants
Mutationswere generated by site-directedmutagenesis of SERCA3a/
pcDNA3, SERCA3b/pcDNA3 or SERCA3e/pcDNA3 constructs, using
Quick Change XL Site-directed Mutagenesis Kit from Stratagene (La
Jolla, CA, USA). Several point mutations giving switch amino acids were
performed: Arg198→Ala; Arg334→Ala; Arg396→Ala; Arg638→Ala;
Arg671→His; Lys712→Ala; Lys713→Ala; Lys728→Ala for SERCA3a and
Arg1002→Ala for SERCA3b and SERCA3e. A number of double mutants
were also obtained, including Arg334/Arg396→Ala334/Ala396; Arg334/
Arg638→Ala334/Ala638; and Lys712/Lys713→Ala712/Ala713. However, the
double mutant Ala334/Ala396 only gave limited quantities of proteins. All
the SERCA3 mutants were checked by DNA sequencing (Genome
Express, France).
2.5. Preparation of platelet and HEK-293 cell membrane vesicles
Platelet membrane vesicles were isolated as described in [8]. As
concerns the HEK-293 cell membrane vesicles, the cells were
harvested, washed with PBS (pH 7.4) and resuspended in an ice-cold
buffer containing 10 mM KCl, 10 mM K-Hepes (pH 7.0), 50 μM EGTA,
50 μM EDTA, 50 μMphenylmethylsulfonyl ﬂuoride, 100 μg/ml soybean
trypsin inhibitor, 100 μg/ml Bowman-Birk trypsin-chymotrypsin
inhibitor, 100 μg/ml aprotinin and 0.1 mM dithiothreitol (DTT). The
cell suspension was homogenized in a Teﬂon-glass homogenizer and
then sonicated on ice. The lysate was centrifuged at 120 ×g for 10 min
at 4 °C and the supernatant was centrifuged at 100000 ×g for 1 h. The
pellet was resuspended in a buffer containing 160 mM KCl, 17 mM K-
Hepes (pH 7.0) and 0.1 mM DTT, frozen and maintained at −80 °C.
2.6. Controlled proteolysis of membrane vesicles
Trypsin treatment of membrane vesicles was carried out in
proteolysis medium containing 160 mM KCl, 17 mM K-Hepes (pH
7.0), 0.1mMDTT, 0.05mMCaCl2 and 0.1mg/mlmembrane proteins, as
well as either 10 μg or 50 μg/ml trypsin for different time periods. The
reaction was stopped with a 10-fold excess (w/w) of soybean trypsin
inhibitor, as in [8].
2.7. Thapsigargin (Tg) and 2,5-di-(t-butyl)-1,4-benzohydroquinone
(tBHQ) treatment
Membrane vesicles were treated with either 5 μM Tg or 10 μM tBHQ
for 5 min at 37 °C, and subsequently placed on ice for an additional
10 min. Trypsin proteolysis was then performed as described above.
2.8. Ca2+, EGTA and AlF4
− treatments
For Ca2+ and EGTA treatments, membrane vesicles were incubated
in a buffer containing 160 mM KCl, 17 mM K-Hepes (pH 7.0), 0.1 mM
DTT and either 2 mM CaCl2 or 2 mM EGTA, respectively, for 2 min at
room temperature before trypsinolysis. For AlF4− treatment [22],
membrane vesicles were incubated in a buffer containing 100 mM
K-MOPS (pH 7.2), 100 mM KCl, 1 mM MgCl2, and 50 μM AlF4− (20 μl of
5 mMAlCl3 and 200 μl of 20mMNaF) for 20min at room temperature.
After incubation, the buffer was removed by centrifugation at
10000 ×g. The pellet was resuspended in a buffer containing
100 mM K-MOPS and 3 mM EGTA to eliminate all unbound ﬂuoride
and aluminium. After centrifugation at 10000 ×g, the pellet was
resuspended in a buffer containing 160 mM KCl, 17 mM K-Hepes
(pH 7.0) and 0.1 mM DTT before trypsinolysis.
2.9. Antibodies
For SERCA2b, the pan-anti-SERCA2 monoclonal antibody IID8 was
used. All SERCA3proteinswere visualizedusing thepolyclonal N89 (PAI-
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PL/IM430 (generous gift from Pr N. Crawford) [11] and the monoclonal
ATP2A3 (Abnova, Taiwan, Republic of China) pan-anti-SERCA3 anti-
bodies. Isoform-speciﬁc polyclonal antibodies against the SERCA3a–3d
and -3f proteins were also used [10,21,23]. Secondary anti-rabbit and
anti-mouse horseradish peroxidase-conjugated antibodies for immu-
noblottings came from Jackson Immunoresearch (West Grove, PA, USA).
2.10. Generation and characterization of a novel human SERCA3e-speciﬁc
polyclonal antibody
A SERCA3e-speciﬁc polyclonal antibody was generated by immu-
nizing SPF rabbits with a mixture of the P1 and P2 peptides, as
indicated in Fig. 7A (Eurogentec, Herstal, Belgium). Eurogentec also
performed the afﬁnity puriﬁcation of antiserum using each peptide.
Puriﬁed anti-SERCA3e-P1 and anti-SERCA3e-P2 antibodies wereFig. 1. Demonstration of two tryptic proﬁles of SERCA3a protein in human platelets. (A) Locati
monoclonal ATP2A3 and polyclonal isoform-speciﬁc anti-SERCA3a (Anti-3a) antibodies rec
membrane vesicles (0.1mg/ml) were proteolyzed using 50 μg/ml trypsin at 4 °C for the time p
by electrophoresis on 10% SDS-PAGE (50 μg of membrane proteins/lane), blotted onto ni
fragments A to H are positioned on the left-hand side. In this and the following ﬁgures, th
representation of the accessibility of tryptic sites at 1 and 5 min of trypsin proteolysis of pltested by immunoblotting using recombinant SERCA3e protein (data
not shown). The puriﬁed anti-SERCA3e-P2 antibody presented the
highest immunoreactivity and was used for all immunoblotting
experiments within the present study.
2.11. Electrophoresis of proteins and Western blotting
Protein electrophoresis was performed using either 7.5% acidic SDS-
PAGE for the analysis of phosphoenzyme intermediate formation of
SERCA3 isoforms or 10% SDS-PAGE for Western blotting of intact and
proteolyzed SERCA3 proteins. After electrophoresis, the separated
proteins were transferred onto nitrocellulose membranes. For Western
blotting of SERCA3 proteins, nitrocellulose membranes were incubated
with a 1:1000 dilution of N89, 1 μg/ml of PL/IM430, a 1:1000 dilution of
ATP2A3 or a 1:1000 dilution of each of the isoform-speciﬁc antibodies
against SERCA3a–3f, in Tris-buffered saline (10 mM Tris/HCl andon of the epitopes of the anti-SERCA3 antibodies. Polyclonal N89, monoclonal PL/IM430,
ognize aa 29–39, 1–40 and 126–230, 501–621 and 991–999, respectively. (B) Platelet
eriods indicated. The intact (0) and trypsin-proteolyzed Ca2+ ATPases were then resolved
trocellulose membranes, and immunostained using the antibodies indicated. Tryptic
e molecular weight markers in kDa are located on the right-hand side. (C) Schematic
atelet SERCA3a protein. This ﬁgure is typical of 4 experiments.
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room temperature. After washing, blots were treated with a 1:10000
dilution of horseradish peroxidase-conjugated anti-rabbit IgG (N89 and
anti-SERCA3a–3f) or a 1:2000 dilution of horseradish peroxidase-
conjugated anti-mouse IgG (IID8, ATP2A3 and PL/IM430). Antibody
binding was revealed using enhanced chemiluminescence Western
blotting reagents, as per the manufacturer's instructions. Luminograms
were quantiﬁed using the Fuji LAS 3000 luminescent Image Analyzer
and Multi-Gauge software (FujiFilm, Japan).
2.12. Phosphoenzyme intermediate of intact and proteolyzed
SERCA3 isoforms
Phosphorylation of SERCA3 enzymes with [γ-32P]ATP (0.05 μM
ﬁnal concentration) was carried out for 1 min at 4 °C in the proteolysis
medium, immediately after proteolytic digestion, as described earlier
[8,15]. The reaction was stopped by adding trichloroacetic acid (6%)
solution containing phosphoric acid (10 mM) and ATP (1 mM). The
precipitateswere thenwashed three timeswith the same solution and
ﬁnally dissolved in the electrophoresis sample buffer [8].
2.13. Calculation of the molecular weight (MW) of the tryptic fragments
For this, the ratio between the MW in kDa of the SERCA3a–3f
isoforms and their number of aa was calculated. The mean value of
1 kDa for 9.15 aa was obtained. The aa (s) identiﬁed on the basis of the
effect of their mutations on the tryptic proﬁles were used to calculate
the length of the fragments in aa and their resulting MW.
Data in the present work relate to at least three independent
experiments and are presented mainly in the form of representative
experiments.Fig. 2. Demonstration of two tryptic proﬁles of stable recombinant human SERCA3a pro
transfected in HEK-293 cells. HEK-293 cell membrane vesicles (0.1 mg/ml) were proteolyze
intact and trypsin-proteolyzed SERCA3a proteins were then treated for Western blotting an
10 μg/ml and 50 μg/ml trypsin.3. Results
3.1. Co-expression of two SERCA3a conformational states in
human platelets
For this, we performed tryptic digestion of platelet membranes
mainly expressing SERCA3a [10], followed by Western blotting using
antibodies recognizing the N-terminal (N89) [9] and (PL/IM430) [11],
middle (ATP2A3) and C-terminal (Anti-3a) [10] parts of SERCA3a
protein (Fig. 1A). Fig. 1B and C show the time course of trypsinolysis
using 50 μg/ml trypsin at 4 °C for the time periods indicated allowing
the dissociation of two distinct Early (1 min) and Late (5 to 10 min),
Tryptic Fragmentations of SERCA3a. They are named ETF and LTF,
respectively, in the following. At 1 min, the parent B/C (73/68-kDa)
and D/E (40-kDa) fragments resulting from T1/T2 and T3/T4 tryptic
sites, respectively, were detected by both PL/IM430 and N89
antibodies, establishing that they belong to the N-terminal part of
SERCA3a. A complementary C-terminal A (32-kDa) fragment of the B/C
fragments resulting from T1/T2 trypsin attack was detected by the
Anti-3a antibody. The B/C and an additional F (33-kDa) fragmentswere
recognized by ATP2A3 antibody. This intermediate F fragment comes
from the B/C fragments as a result of trypsin attack at T3/T4 tryptic
sites.
Later on, i.e. at 5 to 10 min, the disappearance of these fragments
was accompanied by the appearance of a second tryptic fragmenta-
tion pattern (LTF), giving rise to C-terminal G (80-kDa) and N-terminal
H (22-kDa) fragments recognized by both Anti-3a and ATP2A3, and
N89 antibodies, respectively. Obviously, the G fragment, longer than
the longest B/C fragments of ETF, could not belong to the ETF.
Therefore, these fragments were issued from another single trypsin
attack at T5 site.tein: time-course and dose–response effects of trypsin. SERCA3a protein was stably
d using either 10 (A) or 50 μg/ml (B) trypsin at 4 °C for the time periods indicated. The
d are presented as in Fig. 1. This ﬁgure is typical of 4 experiments on the effect of both
Table 1
Arg residues Lys residues
aa SERCA1a SERCA3a aa SERCA1a SERCA3a aa SERCA1a SERCA3a
14 − + 502 − + 47 + +
33 − + 505 + − 120 + +
35 − + 524 + + 135 + +
63 + + 529 + + 158 + +
110 + + 533 − + 169 + +
131 + + 542 − + 189 + +
134 + + 550 − + 204 + +
139 + + 560 + + 205 + +
141 − + 567 + + 218 + +
143 + + 572 − + 234 + +
164 + + 604 + + 252 + +
174 + + 613 − + 297 + +
198 + + 620 + + 329 + +
236 + + 637 + + 352 + +
246 − + 638 + + 431 + +
251 − + 656 + + 436 + +
258 − + 667 + + 476 − +
290 + + 671 + + 481 + +
324 + + 674 − + 492 + +
325 + + 678 + + 511 + +
328 − + 686 − + 515 + +
334 + + 751 + + 548 − +
365 − + 762 + + 573 − +
396 − + 822 + + 583 − +
403 + + 825 − + 629 + +
464 − + 836 + + 651 − +
467 + + 871 − + 684 + +
480 − + 894 − + 712 + +
489 + + 924 + + 713 + +
491 + + 965 − + 728 + +
989 + + 758 + +
819 − +
875 − +
985 + +
Amino acid similarity comparison.
+ : Presence - : Absence.
Black : Homology.
Red : Divergence.
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human SERCA3a protein
To further identify the SERCA3 tryptic sites by site-directed
mutagenesis, we used the recombinant human SERCA3a protein
expressed in HEK-293 cells [20]. As a prerequisite, we looked for
similarities with human platelets. Fig. 2 shows both a reﬁned time
course and dose response of the effect of trypsin on stable
recombinant SERCA3a protein. Using 10 μg/ml trypsin for 0.5 to
15 min (Fig. 2A), one could see that at 0.5 min, the ﬁrst tryptic site
was the T1 site, which gave rise, to the concerted A and B fragments
recognized by the Anti-3a antibody (A) and the PL/IM430, N89 or
ATP2A3 antibodies (B), respectively. At 5 to 15 min proteolysis, the
appearance of the C, D/E and F fragments was observed as well as a
slight decrease in the level of A fragment. In this experimental setup
(low trypsin concentration), G and H fragments could not be
visualized. At 50 μg/ml trypsin concentration (Fig. 2B), differences
appeared in the time-course of the appearance and disappearance of
the fragments identiﬁed in the ETF. The A fragment appeared
transiently. The B fragment disappeared at 5 min, while the intensity
of the D/E doublet and F fragment was maximal at 5 min and then
disappeared. The major differences reside in the apparition of G and
H fragments, which appeared maximal at 5 to 15 min proteolysis.
Thus, the ETF and LTF proﬁles of recombinant SERCA3a protein
exhibited great similarities with those of human platelet SERCA3a
protein.
We also tested the effect of trypsin on SERCA3a protein transiently
expressed in HEK-293 cells. Similar results were observed (data not
shown), thus further establishing the dissociation between the two
tryptic proﬁles.3.3. Prediction of tryptic sites involved in SERCA3a tryptic fragmentations
To predict tryptic sites for ETF of SERCA3a, we at ﬁrst looked for
sequence alignments of human SERCA1a and SERCA3a. Table 1 sum-
marizes the Arg and Lys residues present in the two isoforms. SERCA3a
contains 60 Arg versus 37 for SERCA1a. All Arg residues present in
SERCA1a are found in SERCA3a except Arg505 (one of the two major
tryptic sites, T1, in SERCA1a). About Lys residues, SERCA3a contains 34
Lys versus 27 for SERCA1a. Again, all Lys residues present in SERCA1a
are found in SERCA3a. Second, we focused on ﬁndings on rabbit
SERCA1a showing 3 tryptic sites known as T3 (Arg334), T4 (Arg638 or
Arg639) and T5 (Lys728) when skeletal muscle sarcoplasmic reticulum
membranes were extracted in the presence of EDTA before trypsiniza-
tion [24]. These tryptic fragments of SERCA1a could display simila-
rities with the B/C and D/E fragments of SERCA3a. Third, some
preliminary assays for the modeling of the structures of SERCA3 in E1
and E2 conformations (personal data, Pr J.T. Penniston, Massachusetts
General Hospital, Boston, USA) suggested different accessibility for
Arg396 and Arg403 in the two conformational states. Fourth, the
approximate locations of either Arg or Lys residues, as a function of the
estimated MW of the fragments of ETF, were also tested with the
inclusion of Arg671 and Lys712/Lys713. Last, to predict the cleavage site
for LTF, wewere helped by previous data suggesting the identity of the
T5 tryptic site (Fig. 1C) with the T2 tryptic site of SERCA1a [9].
3.4. Identiﬁcation of Arg334 and Arg396 as candidate tryptic sites in early
tryptic fragmentation
Fig. 3 shows the results of the effects of 50 μg/ml trypsin for 1 to
5 min on transiently transfected Wild Type SERCA3a (WT) and its
Fig. 3. Involvement of Arg334 and Arg396 in early tryptic fragmentation. Recombinant SERCA3a protein was mutated at either Arg334 or Arg396. Mutated proteins were transiently
transfected in HEK-293 cells and membrane vesicles were proteolyzed using 50 μg/ml trypsin for the time periods indicated. The intact and trypsin-proteolyzedWild Type (WT) and
R334A (334) or R396A (396) mutated SERCA3a proteins were then treated for Western blotting as in Fig. 1. (A) Effect of R334A mutation; (B) Effect of R396A mutation; (C) Schematic
representation of the effect of both R334A and R396A mutations on tryptic fragmentation. This ﬁgure is typical of 5–7 experiments. (D) Based on the sequence similarity of SERCA3a
with SERCA1a, the trypsin cleavage sites (in yellow) of SERCA3a are mapped on the atomic model of SERCA1a in the E1 state (Protein Data Bank code 1su4). R334 (R334 in SERCA3a)
and L396 (R396 in SERCA3a) are shown.
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exception of some destabilization of R396A mutant (it disappears
more quickly than the WT), striking similarities appear in the
mutagenesis-related changes of the tryptic proﬁles. These mutations
were found to abolish or inhibit the second step of ETF (i.e. the
fragmentation of the B/C doublet) and to markedly decrease LTF (i.e.
the formation of G and H fragments). Both mutations clearly sup-
pressed the D fragment and inhibited the E fragment of the D/E
doublet as shown by both the PL/IM430 and N89 antibodies, and
blocked the formation of F fragment recognized by the ATP2A3
antibody. This was consistent with the concerted apparition of D/E
and F fragments in WT SERCA3a as a result of trypsin attack at T3/T4
sites. This led us to calculate the exact MWof D fragment as 36.5-kDa.
As expected, trypsinolysis of these SERCA3a mutants exhibited similar
A fragment. In addition, a concerted decrease in appearances of G and
H fragments was observed in both mutants as shown by ATP2A3 and
Anti-3a antibodies for G fragment and N89 antibody for H fragment.
Thus, R334A and R396A mutants were also found to inhibit the
accessibility of the T5 tryptic site involved in LTF.
To understand the similarities between the effects of R334A and
R396A mutations on ETF (Supplemental Fig. 1) we reﬁned the
experimental conditions of Western blotting with PL/IM430 (panel A)
and ATP2A3 (panel B) antibodies. Supplemental Fig. 1A establishes
that the proteolysis of the two mutants shows the absence of D
fragment and the inhibition of the formation of E fragment (trypsin
attack at Arg324?). An additional I fragment was also observed.Supplemental Fig. 1B shows that the absence of F fragment was
compensated by the J fragment of higher MW (trypsin attack at
Arg290?) in both mutants, added to a K fragment of lower MW in
R334A mutant, only. This smaller fragment is obviously due to trypsin
attack at Arg396, as it is totally absent in R396A mutant. In addition, its
lower MW is consistent with the expected difference of 6.7-kDa
corresponding to the 62 aa long region between Arg334 and Arg396
tryptic sites. Thus, the tryptic proﬁles observed in the two mutants
can be explained by the fact that R334A mutation induces the
accessibility of Arg396 while R396A mutation prevents that of Arg334
(Supplemental Fig. 1C).
3.5. Identiﬁcation of Arg638 as candidate tryptic site in early
tryptic fragmentation
Fig. 4 shows the ETF proﬁles of R638A mutant and R334A/R638A
double mutant. When using R638A mutant, the appearance of the B/C
doublet was inhibited as shown by either the PL/IM430 (Fig. 4A) or the
ATP2A3 (Fig. 4B) antibodies. This mutant was also found to exhibit
similarities with R334A and R396A ones as concerns the disappear-
ance of both the D and F fragments (Fig. 4A and B, respectively). Thus,
the mutation of Arg638 abolished the accessibility of Arg334 (Fig. 4C).
We also compared the effect of R638A mutation with that of the
R334A/R638A double mutation. Interestingly, the B/C doublet was
present in the ETF proﬁle of this double mutant, may be due to a
tryptic attack at Arg637 instead of Arg638. Immunostaining with
Fig. 4. Involvement of Arg638 in early tryptic fragmentation. (A and B) Comparative effect of the mutation of Arg638 and of Arg334/Arg638 on early tryptic fragmentation induced
by 50 μg/ml trypsin for the time periods indicated. WT, R638A (638) and R334A/R638A (334/638) mutated SERCA3a proteins were treated for Western blotting as in Fig. 1. (A)
PL/IM430; (B) ATP2A3. (C) Schematic representation of the effect of the mutation of Arg638 on the accessibility of Arg334. This ﬁgure is typical of 3–4 experiments. (D) In a
similar manner as in Fig. 3D, R638 (R638 in SERCA3a) is shown.
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MW, theymay refer to trypsin attack at Arg290 and Lys352, respectively.
The identiﬁcation of the Arg638 tryptic site led us to calculate the exact
MW of F fragment as 33.2 kDa.
3.6. Involvement of Arg671, Lys712/Lys713 and Lys728 in early
tryptic fragmentation
In a further attempt to identify the T1/T2 tryptic sites, we studied the
R671H, K712A/K713A and K728Amutants.While thesemutants did not
directly abolish the T1/T2 tryptic sites as visualized by PL/IM430 and
ATP2A3 antibodies, mutants induced an increase in F and D fragments,
respectively,while doublemutantK712A/K713A induced a decrease inA
fragment (data not shown). So, these tryptic sitesmay verywell account
for the possible multi-tryptic sites implicated in the initial C-terminal
fragmentation.3.7. Identiﬁcation of Arg198 as tryptic site in late tryptic fragmentation
For this, we took advantage of previous works on both SERCA1a
and SERCA3 proteins. SERCA1 and SERCA2 proteins present two
major tryptic sites termed T1 (Arg505) and T2 (Arg198) [25–29]. A
SERCA-related fragment of about 80-kDa had been described upon
trypsin proteolysis of platelet membranes and recombinant SERCA3a
protein [8,9,12–15]. It was suggested that the formation of this
fragment may appear in the absence of the T1 tryptic site (Arg505) of
SERCA1 and SERCA2 in SERCA3 (Table 1). However, the exact identity
of the tryptic site of SERCA3a, with the T2 site (Arg198) of SERCA1 and
SERCA2, was not demonstrated at that time. Here, by using R198A
SERCA3a mutant, we clearly identiﬁed it as the T5 tryptic site that
gives rise to G and H fragments (Fig. 5). R198A mutation shows that
neither the C-terminal G fragment (recognized by both ATP2A3 and
Anti-3a antibodies), nor the N-terminal H fragment (recognized by
Fig. 5. Involvement of Arg198 in late tryptic fragmentation. (A) Recombinant SERCA3a protein was mutated at residue Arg198 (R198A) and transiently transfected in HEK-293 cells.
Membrane vesicles were further proteolyzed using 50 μg/ml trypsin for the time periods indicated. Wild Type (WT) and mutated SERCA3a protein (Arg198) were then treated for
Western blotting as in Fig. 1. (B) Schematic representation of the effect of the mutation of Arg198. This ﬁgure is typical of 5 experiments. (C) In a similar manner as in Figs. 3D and 4D,
R198 (R198 in SERCA3a) is shown.
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to calculate that the G and H fragments exhibit exact MW of 87.5-
and 21.5-kDa, respectively. In addition, and as expected, R198A
mutation had no effect on the ETF of SERCA3a. This led us to think
that Arg198 (T5 tryptic site) is hidden in the SERCA3a conformation
giving rise to the ETF proﬁle of this enzyme.
3.8. Effect of SERCA inhibitors thapsigargin (Tg) and tert-butyl
benzohydroquinone (tBHQ) on tryptic fragmentation of SERCA3a
In order to further establish the two conformational states of
SERCA3a, we checked whether modulation of its two tryptic frag-
mentation proﬁles occurred upon addition of 5 μM Tg (Supple-
mental Fig. 2) or 10 μM tBHQ (data not shown) for up to 10 min at
37 °C before trypsinolysis. These SERCA inhibitors were previously
shown to induce the so-called E2(Tg) state of SERCA1a [4,18].
Supplemental Fig. 2 shows that Tg slightly modiﬁed the ETF, and
that the modiﬁcation displayed similarities with what was ob-
served with the R334A mutant. A decrease in the recognition of the
D/E doublet by the PL/IM430 and N89 antibodies was observed, due
purely to the abolishment of the D fragment. This observation was
associated with the disappearance of F fragment visualized byNotes to Figure 5.
(We were also surprised by the apparent higher expression of SERCA3a in R198A mutant, d
amounts of proteins deposited on the gels by using Ponceau Red, we found no differences be
see that differences exist between the antibodies, as for example, N89 antibody could detect
that PL/IP430 antibody is now deﬁned as a conformational antibody [11]. In this context, w
membrane preparations was apparently lower (unpublished data).)ATP2A3 antibody. As regards LTF, no major modiﬁcation was ob-
served, as both G and H fragments were still present as visualized
by ATP2A3, Anti-3a and N89 antibodies, respectively. Again, no
major modiﬁcation of the ETF and LTF was made using 10 μM tBHQ
(data not shown).
3.9. Effect of Ca2+, EGTA and AlF4
− on tryptic fragmentation of SERCA3a
In order to check whether the ETF does not reﬂect the presence of
partially unfolded protein in our membrane preparations, we tested
the effects of 2 mM CaCl2, 2 mM EGTA and 50 μM AlF4− (a phosphate
mimic [22]) on tryptic fragmentation of SERCA3a. Fig. 6 shows that
Ca2+, EGTA and AlF4− strongly affected the ETF without modifying the
LTF. Moreover, differences were found according to the treatment.
The addition of either CaCl2 or AlF4− inhibited the ETF as shown by the
decrease in B/C and D/E fragments seen by PL/IM430 and N89, as well
as by the decrease in F fragment visualized by ATP2A3 antibody,
respectively. Conversely, EGTA was found to increase the ETF as
shown by the increased intensity of same D/E and F fragments. In
contrast, various additions, Ca2+, EGTA or AlF4−, did not affect the
appearance of the H fragment (shown by the N89 antibody) in the
LTF proﬁle of SERCA3a.etected with the PL/IM430, ATP2A3 and Anti-3a antibodies. Indeed, when verifying the
tweenWTand R198A mutant. Moreover, by comparing the different antibodies, one can
almost same amounts of WT and R198A mutant. We should also take into consideration
e also observed that after autophosphorylation, N89 recognition of SERCA3a in platelet
Fig. 6. Comparative effects of Ca2+, EGTA and AlF4− on early and late tryptic proﬁles. Recombinant SERCA3a protein was transiently transfected in HEK-293 cells. Membrane vesicles
were treated with either 2 mM CaCl2, 2 mM EGTA or 50 μM AlF4− as described under Materials and methods. Membrane vesicles were further proteolyzed using 50 μg/ml trypsin for
the time periods indicated and treated for Western blotting using the antibodies indicated. A, Untreated membrane vesicles (50 μM CaCl2 in the proteolysis medium). B, Membrane
vesicles treated with CaCl2. C, Membrane vesicles treated with EGTA. D, Membrane vesicles treated with AlF4−. The ﬁgure is typical of 4 experiments.
595E. Corvazier et al. / Biochimica et Biophysica Acta 1788 (2009) 587–5993.10. All recombinant human SERCA3a–SERCA3f isoforms exhibit similar
tryptic fragmentation proﬁles
Studies to investigate the intrinsic properties of the various
recombinant human SERCA3 isoforms showed a similar reduced afﬁnity
towards Ca2+ compared to SERCA1. However, analysis of the catalytic
cycle of SERCA3a, -3b, -3c and -3f isoforms revealed differences in
the dephosphorylation of the E2P intermediate of these enzymes
[21,30]. This led us to look for the tryptic fragmentation proﬁles of
the SERCA3a–3f isoforms (Fig. 7) followed byWestern blotting using the
PL/IM430, N89 and isoform-speciﬁc anti-SERCA3a–3f antibodies.
While anti-SERCA3a–3d and -3f antibodies [10,21,23] were available, a
SERCA3e-speciﬁc antibodywas lacking. Such anantibodywas generated
and characterized by testing its immunoreactivity on recombinant
SERCA3a–3f proteins (Fig. 7A,B). The PL/IM430 antibody recognized all
SERCA3 isoformsmigratingat their predictedMW.The anti-SERCA3e-P2
antibody only recognized the recombinant SERCA3e isoform, and this
signal was abolished by the P2 peptide used for immunization.
Subpanels C–E of Fig. 7 show the effect of 50 μg/ml trypsin on stably
transfected SERCA3a–3f isoforms. All isoforms exhibit similar ETF and
LTF, as judged by: i) PL/IM430 (B/C and D/E fragments) (Fig. 7C) and ii)
N89 (H fragment) (Fig. 7D) antibodies. Surprisingly, SERCA3b to
SERCA3e isoforms sometimes appeared to be expressed as protein
doublets recognized by the PL/IM430 (see also Fig. 8). In Fig. 7E, the
isoform-speciﬁc anti-SERCA3a–3f antibodies (see Fig. 7A for their
epitopes) were tested on intact and trypsinolyzed SERCA3a–SERCA3f
proteins. The key observation was that major tryptic digests of about31-, 36-, 34-, 36-, 37- and 35-kDaMWwere recognized by the different
anti-SERCA3a–3f antibodies, respectively. Compared with SERCA3a,
additional 44, 30, 45, 53 and 34 aa long C-terminal ends are present in
SERCA3b, -3c, -3d, -3e and -3f isoforms (see Figs. 7A and 8B). Therefore,
the different C-terminal A fragments of SERCA3b–3f isoforms are
coming from the same tryptic site as that giving rise to the A fragment
of SERCA3a.
3.11. Only SERCA3b–SERCA3e isoforms exhibit an additional tryptic
site at Arg1002
In the protein doublets of the SERCA3b–3e isoforms recognized by
PL/IM430 in trypsin-treated samples (Fig. 7C), the lower protein bands
were not recognized by the anti-SERCA3b–3e antibodies (Fig. 7E). This
observation pointed to an additional tryptic site in the C-terminal
parts of these SERCA3 isoforms. In addition, the lower protein bands
appeared to migrate as SERCA3a. This led us to postulate in favor of a
common tryptic site giving rise to fragments with similar MW to that
of SERCA3a. Fig. 8 establishes these data and identiﬁes this tryptic site
as Arg1002. Through the technique of phosphorylated intermediate
formation (autophosphorylation of Asp351) of stably transfected
SERCA3a–3f isoforms, Fig. 8A demonstrates the appearance of
autophosphorylated doublets in the trypsin-treated SERCA3b–3e
isoforms, which are also recognized by the PL/IM430 antibody. The
doublets were particularly well visualized for the longer SERCA3b, -3d
and -3e isoforms. Fig. 8B shows Arg1002, which is only present in
SERCA3b–3e isoforms (absent in SERCA3a and SERCA3f) as the
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Fig. 8. SERCA3b–3e isoforms exhibit Arg1002 as an additional tryptic site. (A) Microsomal membranes isolated from HEK-293 cells stably transfected with SERCA3a–3f proteins were
submitted to 50 μg/ml trypsin proteolysis at 4 °C for the time periods indicated. Intact and trypsinolyzed Ca2+ ATPases were then labeled with 0.05 μM [γ-32P]ATP for 1 min, resolved
by 7.5% acidic electrophoresis to preserve the aspartylphosphate intermediates of Ca2+ ATPases, blotted and autoradiographed [8,14,15]. This ﬁgure is typical of 3 experiments. (B) C-
termini of human SERCA3 proteins. Slashes mark the ﬁrst splice site. The sequence underlined represents the amino acid stretch used for SERCA3b immunization. The amino acids
framed show the presence of Arg1002 in SERCA3b to -3e isoforms. (C) Recombinant SERCA3b protein was mutated at residue Arg1002 (R1002A) and transiently transfected in HEK-293
cells. Membrane vesicles were proteolyzed using 50 μg/ml trypsin for the time periods indicated. Wild Type (WT) and mutated SERCA3b proteins (R1002A) were then treated for
Western blotting using PL/IM430 (left) and the isoform-speciﬁc anti-SERCA3b antibody (right). This ﬁgure is typical of 3 experiments.
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Fig. 8C shows the effect of Arg1002 mutation (R1002A) on the tryptic
fragmentation of one of the SERCA3b–3e isoforms, SERCA3b transi-
ently transfected in HEK-293 cells. As expected, no protein doublet
was detected upon trypsin proteolysis of the mutated SERCA3b
protein, as shown by the PL/IM430 antibody. Reprobing the blots with
the anti-SERCA3b antibody showed no differences in its recognition of
a single protein band corresponding to either WT or R1002A mutant
intact SERCA3b proteins. This is fully consistent with the lack of
recognition of the SERCA3b truncated at Arg1002 by the antibody. The
same study was performed on WT and mutant (R1002A) SERCA3e
isoforms, which gave similar results as those obtained using SERCA3b
(data not shown).Fig. 7. All SERCA3a–3f isoforms exhibit similar early and late tryptic proﬁles. (A and B) Gen
proteins. Slashes indicate the splice sites. The framed sequences represent the peptides us
proteins were isolated from HEK-293 cells stably transfected with empty vector pcDNA3.1
monoclonal pan-SERCA2 (IID8), the monoclonal pan-SERCA3 (PL/IM430) and the polyclonal
were treated either in the absence or presence of 10 μM peptide (P2). The numbers indicate
vesicles were proteolyzed using 50 μg/ml trypsin and further treated for Western blotting
antibodies (E). The numbers on Fig. 7E indicate the calculated molecular masses of A fragm4. Discussion
Some twenty years ago we only knew the primary structure on
several P-type ATPases. In that time tryptic digestion experiments
were very useful tools to get information on the structure and
conformational changes in these P-ATPases. Since 2000 [3] we know
the crystal structure of SERCA1a and recently structures of Na+, K+-
ATPase [31] and plant H+-ATPase [32]. In addition, a large number of
modeling studies have shown that the gross structure of the P-type
ATPases is rather similar. As mentioned in the Introduction, in the
intracellular domain of these transporters, A-, P- and N-subdomains
can be recognized that undergo domain movements during the
catalytic cycle. However, to answer the question of the physiologicaleration of a novel SERCA3e-speciﬁc antibody. (A) C-terminal sequences of SERCA3a–3f
ed for the different immunizations (Peptides P1 and P2 for SERCA3e). (B) Membrane
and SERCA3a–f cDNAs. Microsomes (10 μg) were used for Western blotting using the
anti-SERCA3e antibodies. To test the speciﬁcity of the anti-SERCA3e antibody, the blots
the calculated protein molecular masses in kDa. (C–E) SERCA3a–3e membrane protein
s using the PL/IM430 (C), N89 (D) and the various isoform-speciﬁc anti-SERCA3a–3f
ents of the various isoforms, in kDa. This ﬁgure is typical of 6–7 experiments.
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environment, other approaches have to be used. For this, again,
changes in the pattern of tryptic proteolysis appeared to be a
complementary technique. Accordingly, very recently, conformational
ﬂuctuations of SERCA1a in the native membrane environment have
been described using proteolytic fragmentation approach with
proteinase K or trypsin [18]. Here, by performing trypsinolysis of
SERCA3 proteins in native human cell membranes, we described two,
kinetically distinct, ETF and LTF proﬁles and identiﬁed some of the
proposed T1–T5 tryptic sites (Fig. 1). T1–T2 would be a multi-tryptic
site in the 638–728 region. T3–T4 would be a multi-tryptic site in the
290–396 region. T5 is at 198. In addition, a ﬁnal tryptic site has been
positioned at 1002 in SERCA3b–3e isoforms.
A study of SERCA3 gene products is of interest for the following
reasons at least: i) they are expressed in a number of cells and tissues
[20,21,33,34]; ii) mutations in SERCA3 gene have been described in
patients with type II diabetes mellitus and squamous cell carcinoma
[35,36]; iii) lack of SERCA3 altered endothelium- and epithelium-
dependent relaxation in vascular smooth muscle [37,38]; iv) modu-
lated SERCA3 expression has been documented during cell differ-
entiation [39–43]; v) different roles of SERCA3b and -3f isoforms in
cell function have been identiﬁed [44]; vi) a role of SERCA3 was very
recently described in the mechanism of store-operated Ca2+ entry, a
process that is very relevant in many cell functions [45–47].
In addition, as mentioned in the Introduction, early studies
revealed a number of functional particularities of SERCA3a in the
SERCA family. The ﬁrst was its lower afﬁnity towards Ca2+ than that
observed for the SERCA1a, -2a and -2b proteins [7]. A second
observation stemmed from studies using human platelets, which
mainly express the SERCA3a isoform along with the SERCA2b isoform
[48,49]. We showed that Tg and tBHQ inhibit Ca2+ uptake of mixed
platelet membrane vesicles [50]. Intriguingly, SERCA3a was found to
exhibit a lower sensitivity to Tg than SERCA2b [14]. Similar
observation was recently made when using recombinant SERCA3a
protein [51]. Conversely, SERCA3a was much more sensitive to tBHQ,
than SERCA2b [15]. In addition, when we performed E∼P formation
and subsequent trypsinization of platelet membranes in the presence
of either Tg or tBHQ (under experimental conditions that only detect
the LTF), we observed that Tg slightly, while tBHQ almost totally
inhibited the formation of the autophosphorylated 80-kDa fragment
(G fragment in the present work) [8,14,15].
Here, using various anti-SERCA3 antibodies and limited trypsino-
lysis of SERCA3a (WT and mutants), we uncovered initial evidence for
the ETF and LTF proﬁles of either human platelet SERCA3a protein, or
transient and stable recombinant SERCA3a–3f isoforms coming from
two SERCA3 conformational states.
The two distinct ETF and LTF proﬁles belong to SERCA3(s) as shown
by their recognitionwith a variety of anti-SERCA3 antibodies. The two
proteolytic patterns have been primarily dissociated on the basis of
their different kinetics of trypsin proteolysis. Indeed, the late
appearance of the longer G fragment in LTF cannot be explained
with the progressive proteolytic proﬁle of ETF. In addition, we showed
that the mutation of Arg198, that blocked the formation of the G and H
fragments, only affected LTF without any effect on ETF. Last, ETF alone
was found to be sensitive to Ca2+, EGTA and AlF4−. In addition, based on
the similarity of the Ca2+ and EGTA lanes, we can suggest that the
SERCA3 population susceptible to T1–T4 (ETF) is in a close to E2
conformation.
We identiﬁed a number of tryptic sites involved in the ETF proﬁle
and a unique tryptic site involved in the LTF proﬁle of the SERCA3
protein(s). For themore complex ETF, the direct involvement of Arg334,
Arg396 and Arg638 has been documented. We also tested the potential
implication of Arg671, Lys728 and Lys712/713 in ETF, and found that these
residues might account for the multi-tryptic site involved in the initial
C-terminal fragmentation of SERCA3(s). In addition, two other tryptic
sites were also suggested. First, based on the MWs of D and F frag-ments, we thought that Arg324 is the tryptic site that gives rise to the E
fragment. Second, based on the results with R334A and R396A
mutants, the ETF of which showed an additional fragment with higher
MW than that of the F fragment, a trypsin attack at Arg290 could also
be suggested. Arg365, Arg403, Arg613 and Arg686 were also mutated, but
these mutations did not modify the ETF. For LTF, Arg198 has been
deﬁnitely identiﬁed as major tryptic site. Lastly, thanks to the coupled
use of the generation of autophosphorylated intermediates, and
Western blottings, we were able to identify Arg1002 as an additional
tryptic site common to SERCA3b to -3e isoforms.
In an attempt to gather further information about the ETF and LTF
of SERCA3a, we studied the effect of SERCA inhibitors inducing the so-
called E2(Tg) conformational state of SERCA1a. Here, by using
recombinant SERCA3a protein, we found that both Tg and tBHQ
slightly inhibited the ETF proﬁle.
The ETF and LTF proﬁles were found not only for the SERCA3a
isoform, but also for the other SERCA3b to -3f isoforms. We uncovered
an additional tryptic site in the SERCA3b–3e isoforms as well, which is
absent in SERCA3f. While the rationale for the diversity of SERCA3
isoforms remains to be understood, some differences have already
been identiﬁed, including differences between SERCA3a, -3b, -3c and -
3f in one of the steps of their catalytic cycles [21,30]. In addition, we
recently observed that the SERCA3a, -3d and -3f isoforms also exhibit
distinct locations in human heart. While SERCA3a was expressed in a
uniform manner, SERCA3d and -3f were restricted to the nucleus and
to the periphery of the cardiomyocyte, respectively [23]. The absence
of Arg1002 in SERCA3f adds an additional difference to those published
previously between the SERCA3 isoforms.
To conclude: 1) the present ﬁndings constitute evidence for co-
expressionof SERCA3proteins in two conformational states in thenative
membrane environment. Can SERCA3 be a physiological prototype of
SERCA in two major conformational states of SERCA1a? 2) Given the
enigma of the lower Ca2+-afﬁnity of SERCA3 isoforms towards Ca2+
compared to those of SERCA1 and SERCA2 proteins, and the expression
of SERCA3(s) in two conformational states including a close to E2
conformation, can these ﬁndings provide an initial explanation? 3) Such
a particularity of SERCA3(s) would also explain the location of at least
some of the isoforms in the subplasmalemmal area of cells, such as
SERCA3f in the heart, where cellular Ca2+ concentration is higher. 4) The
ﬂuctuation of SERCA3 in the two major conformational states may also
be needed for turning on/out a store-operated Ca2+ channel. Indeed, we
recently observed the association of SERCA3 with the STromal Interac-
tion Molecule 1 (STIM1) [47] the ER-resident Ca2+ binding protein that
participates in various signaling complexes regulating the function of
store-operated Ca2+ channels [for reviews see [52,53].
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